Wave Life Sciences
WVE · Nasdaq · Singapore / United States
Share price · WVE
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when WVE's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 16 Nov 2026-8.3%
- 1 Oct 2026+4.9%
Nothing announced by WVE that day or the session before.
- 17 Aug 2026-5.9%
Nothing announced by WVE that day or the session before.
- 11 Aug 2026-16.9%
Nothing announced by WVE that day or the session before.
- 26 Mar 2026-49.6%
- 16 Mar 2026-4.7%
Nothing announced by WVE that day or the session before.
- 8 Dec 2025+147.3%
Share of unusual movement by asset
For each asset, the share of WVE's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(4 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1/2 | DMD exon 53RNA / oligonucleotide | Duchenne Muscular Dystrophy | |
| Phase 1/2 | Huntingtin (HTT)RNA / oligonucleotide | Huntington's Disease | |
| Phase 1/2 | SERPINA1 Z-allele mRNA (ADAR-mediated editing)RNA / oligonucleotide | Alpha-1 Antitrypsin Deficiency | |
| Phase 1/2 | INHBE (Inhibin beta E chain / Activin E)RNA / oligonucleotide | Obesity |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
2029 (1)
March 2029 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $13M | $54M | $197M+ $233M short-term inv. | $62M-$60M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $2.3M | $51M | $368M+ $123M short-term inv. | $69M-$54M operating cash flow | report ↗ |
| 2026-Q1 | $38M | $47M | $545M | $26M-$60M operating cash flow | report ↗ |
| 2025-Q3 | — | $46M | $196M | $54M-$45M operating cash flow | report ↗ |
| 2025-Q2 | $8.7M | $43M | $208M | $50M-$46M operating cash flow | report ↗ |
| 2025-Q1 | $9.2M | $41M | $243M | $47M-$63M operating cash flow | report ↗ |
| 2024-Q3 | — | $41M | $311M | $62M-$46M operating cash flow | report ↗ |
| 2024-Q2 | $20M | $40M | $154M | $33M-$27M operating cash flow | report ↗ |
| 2024-Q1 | $13M | $33M | $181M | $32M-$33M operating cash flow | report ↗ |
| 2023-Q3 | $49M | $32M | $140M | —-$34M operating cash flow | report ↗ |
| 2023-Q2 | $22M | $33M | $173M | $21M-$37M operating cash flow | report ↗ |
| 2023-Q1 | $13M | $31M | $208M | $27M$86M operating cash flow | report ↗ |
| 2022-Q3 | $0.3M | $28M | $97M+ $25M short-term inv. | $39M-$26M operating cash flow | report ↗ |
| 2022-Q2 | $0.4M | $30M | $123M+ $25M short-term inv. | $41M-$29M operating cash flow | report ↗ |
| 2022-Q1 | $1.8M | $27M | $62M+ $50M short-term inv. | $38M-$40M operating cash flow | report ↗ |
| 2021-Q3 | $36M | $31M | $124M | $6.2M-$28M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $43M | $183M | $602M+ $0 short-term inv. | $51M-$187M operating cash flow | report ↗ |
Wave Life Sciences reported full-year 2025 revenue of $42.73M, down 60.5% YoY, with R&D spend of $182.78M, up 14.5% YoY. The company ended the year with cash and equivalents of $602.07M and reported a net loss of $204.38M.
Management guided to a cash runway into 3Q 2028 and highlighted ongoing clinical progress: WVE-007 data updates from the INLIGHT study are expected in 1Q 2026, with a Phase 2a multidose portion planned for 1H 2026 and additional trials as an incretin add-on and post-incretin maintenance in 2026. WVE-006 regulatory feedback on a potential accelerated approval pathway is anticipated mid-2026, with 400 mg multidose data expected in 1Q 2026; a CTA submission for WVE-008 is planned for 2026, and an NDA filing for WVE-N531 remains on track for 2026. Additionally, GSK selected a fourth development candidate under the collaboration, with up to $2.8 billion in potential milestones.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $108M | $160M | $302M | $24M-$151M operating cash flow | report ↗ |
| 2023-FY | $113M | $130M | $200M | $14M-$19M operating cash flow | report ↗ |
| 2022-FY | $3.6M | $116M | $89M | $40M-$128M operating cash flow | report ↗ |
| 2021-FY | $41M | $122M | $151M | $31M-$89M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 5 purchases ($82.6M), 46 sales ($16.1M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-05 | Wagner Heidi L · director | Award / grant | 10,700 | — | — | Form 4 |
| 2026-10-05 | TAKANASHI KEN · director | Award / grant | 10,700 | — | — | Form 4 |
| 2026-10-05 | HENRY CHRISTIAN O · director | Award / grant | 10,700 | — | — | Form 4 |
| 2026-10-05 | Rawcliffe Adrian · director | Award / grant | 10,700 | — | — | Form 4 |
| 2026-10-05 | CORRIGAN MARK · director | Award / grant | 10,700 | — | — | Form 4 |
| 2026-10-05 | Tan Aik Na · director | Award / grant | 10,700 | — | — | Form 4 |
| 2026-10-05 | Verdine Gregory L. · director | Award / grant | 10,700 | — | — | Form 4 |
| 2026-10-05 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M. · director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner | Award / grant | 10,700 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 228 reporting institutions held 172.6M shares ($1.2B, 87.5% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 26,975,505 | $195.6M |
| 2 | GSK plc | 18,245,691 | $132.3M |
| 3 | BlackRock, Inc. | 14,117,412 | $102.4M |
| 4 | MAVERICK CAPITAL LTD | 10,161,399 | $73.7M |
| 5 | Driehaus Capital Management LLC | 5,431,021 | $39.4M |
| 6 | FEDERATED HERMES, INC. | 5,317,457 | $38.6M |
| 7 | FMR LLC | 5,192,761 | $37.6M |
| 8 | 683 Capital Management, LLC | 4,900,000 | $35.5M |
| 9 | PRIMECAP MANAGEMENT CO/CA/ | 4,832,952 | $35.0M |
| 10 | M28 Capital Management LP | 4,588,284 | $33.3M |
| 11 | STATE STREET CORP | 3,674,033 | $26.6M |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 3,579,099 | $26.0M |
| 13 | Siren, L.L.C. | 2,450,000 | $17.8M |
| 14 | CITADEL ADVISORS LLC | 2,202,856 | $16.0M |
| 15 | TWO SIGMA INVESTMENTS, LP | 1,878,115 | $13.6M |